tex10 Antibody

What is TEX10 and what is its biological significance?

TEX10 (Testis Expressed 10) is a protein that functions as a component of the MLL1/MLL complex, which includes core components such as MLL, ASH2L, HCFC1/HCF1, WDR5, and RBBP5. Additionally, TEX10 is part of the PELP1-TEX10-WDR18 complex that regulates ribosome biogenesis, with its distribution controlled by SUMOylation to coordinate ribosome formation rates . This multifunctional protein has emerged as an important player in cancer biology.

Research has revealed significant oncogenic properties of TEX10 across multiple cancer types. In urinary bladder carcinoma, TEX10 protein levels are substantially upregulated in cancerous tissues compared to normal tissues, and patients with low TEX10 expression demonstrate improved disease-free survival (DFS) . Similarly, in esophageal squamous cell carcinoma (ESCC), TEX10 immunostaining is markedly higher in cancerous tissues compared to adjacent non-cancerous tissues .

Functionally, TEX10 promotes proliferation, migration, and invasion of cancer cells, contributing to tumor growth in animal models. Its involvement in cancer stem cell properties, including self-renewal and therapy resistance, suggests TEX10 may serve as both a potential biomarker and therapeutic target in oncology research .

What are the molecular characteristics of commercially available TEX10 antibodies?

Most commercially available TEX10 antibodies are rabbit polyclonal antibodies targeting specific regions of the human TEX10 protein. These antibodies are typically affinity-purified and supplied in liquid format with appropriate preservatives.

Key characteristics include:

The immunogens used to generate these antibodies are often synthetic peptides or fusion proteins corresponding to specific regions of the TEX10 protein . For example, one commercially available antibody targets the middle region of human TEX10 (amino acids 152-201) with the sequence "RLTSQQWRLK VLVRLSKFLQ ALADGSSRLR ESEGLQEQKE NPHATSNSIF" .

What applications are TEX10 antibodies validated for in research settings?

TEX10 antibodies have been validated for multiple research applications across various model systems:

For IHC applications, antigen retrieval is typically recommended using TE buffer at pH 9.0 or citrate buffer at pH 6.0 . Published research has utilized these applications extensively, with multiple studies demonstrating successful TEX10 detection in cancer tissues and cell lines . For instance, TEX10 antibodies have been crucial in demonstrating differential expression between normal and cancerous tissues in urinary bladder carcinoma and esophageal squamous cell carcinoma .

It's important to note that optimal dilutions may vary depending on the specific sample type and experimental conditions, so titration is recommended for each testing system .

How should TEX10 antibodies be optimized for Western blot analysis?

Effective use of TEX10 antibodies in Western blot analysis requires careful optimization of several methodological parameters:

Sample preparation optimization:

• Cells or tissues should be lysed in appropriate lysis buffers containing protease inhibitors to prevent protein degradation

• For cancer studies, paired samples of normal and tumor tissues provide valuable comparative data, as demonstrated in urinary bladder carcinoma research

• Protein quantification and equal loading (typically 20-40 μg total protein) are essential for accurate comparisons

Electrophoresis and transfer considerations:

• Use 8-10% polyacrylamide gels for optimal resolution of TEX10 (95-100 kDa)

• Ensure complete transfer to membrane, as TEX10 is a relatively large protein

• For larger proteins like TEX10, longer transfer times or specialized transfer systems may improve efficiency

Antibody incubation parameters:

• Block membrane thoroughly (5% non-fat milk or BSA in TBST) to minimize background

• Start with 1:1000 dilution of TEX10 antibody and adjust based on signal strength

• Incubate overnight at 4°C for optimal binding

• Include appropriate positive controls (e.g., HeLa cell lysates)

Detection optimization:

• Use appropriate HRP-conjugated secondary antibody (typically anti-rabbit IgG at 1:5000-1:10000)

• For weak signals, consider enhanced chemiluminescence (ECL) substrates

• Expected molecular weight is 95-100 kDa, though calculated weight may be reported as 106 kDa

In published research, Western blot has successfully demonstrated TEX10 expression differences between normal versus cancerous tissues, and verified knockdown efficiency in functional studies . For instance, in urinary bladder carcinoma research, immunoblotting clearly showed low TEX10 expression in normal tissue contrasted with high expression in cancerous tissue .

What protocol modifications are needed for effective immunohistochemical detection of TEX10?

For optimal immunohistochemical detection of TEX10 in tissue samples, researchers should consider these protocol modifications and optimization strategies:

Sample preparation considerations:

• Fixation method and duration significantly impact TEX10 epitope preservation

• Formalin-fixed, paraffin-embedded (FFPE) tissues are commonly used but require optimized epitope retrieval

• Frozen sections may provide better epitope preservation but lower morphological detail

Antigen retrieval optimization:

• Heat-induced epitope retrieval using TE buffer at pH 9.0 is preferred for TEX10 detection

• Alternatively, citrate buffer at pH 6.0 can be used if pH 9.0 buffer gives high background

• Optimize heating conditions (95-98°C for 15-20 minutes) for your specific tissue type

Antibody concentration and incubation:

• Begin with 1:50 dilution for FFPE tissue sections and adjust based on signal intensity

• Extend primary antibody incubation to overnight at 4°C for improved sensitivity

• Use antibody diluent with background-reducing components for cleaner results

Detection system selection:

• Polymer-based detection systems generally provide better signal-to-noise ratio than avidin-biotin systems

• For multiplex applications, consider using tyramide signal amplification (TSA) methods

• Choose chromogen based on co-staining needs (DAB is standard but may interfere with other stains)

Validation approaches:

• Include positive control tissues (human brain tissue is recommended)

• Run parallel negative controls (omitting primary antibody)

• When possible, validate IHC findings with other methods (e.g., Western blot, IF)

Research has demonstrated that TEX10 immunostaining patterns can provide valuable insights into cancer biology. For example, in ESCC, the intensity of TEX10 immunostaining in ESCC tissues was markedly higher compared to adjacent non-cancerous tissues, suggesting its potential as a diagnostic or prognostic marker .

How can researchers use TEX10 antibodies to study the role of TEX10 in cancer stem cell properties?

TEX10 has been implicated in cancer stem cell (CSC) properties, making TEX10 antibodies valuable tools for studying this aspect of cancer biology:

Sphere formation assay analysis:

• Following sphere formation assays with TEX10-manipulated cells (knockdown or overexpression)

• Fix spheroids and perform immunofluorescence staining with TEX10 antibody

• Co-stain with CSC markers to assess correlation between TEX10 and stemness markers

• Quantify sphere number, size, and TEX10 expression levels

Flow cytometry for CSC marker correlation:

• Dissociate cells and perform fixation/permeabilization for intracellular TEX10 staining

• Co-stain with fluorochrome-conjugated antibodies against CSC markers (CD44, CD24, CD133)

• Analyze relationship between TEX10 expression and CSC marker positivity

• Sort TEX10-high and TEX10-low populations for functional assays

Molecular mechanism investigation:

• Perform Western blot analysis to correlate TEX10 expression with stem cell markers

• Use TEX10 antibodies to immunoprecipitate TEX10 and identify interacting proteins involved in stemness

• Conduct chromatin immunoprecipitation (ChIP) using TEX10 antibody to identify genomic regions bound by TEX10, particularly at stemness-related gene promoters

Therapy resistance studies:

• Treat cells with chemotherapeutic agents and analyze TEX10 expression in resistant populations

• Perform immunofluorescence to correlate TEX10 expression with survival following treatment

• Compare TEX10 levels in patient samples before and after therapy failure

Research has demonstrated that TEX10 knockdown leads to decreased expression of stem cell-specific markers (Sox2, Nanog, Oct4) and CSC-associated markers (c-Myc, Bmi1, ABCG2, CD133, CD44, CD24) in esophageal cancer cells . The number and size of spheroids decreased considerably following TEX10 knockdown, indicating its critical role in self-renewal properties . These findings suggest that TEX10 may regulate cancer stemness, making it a potential target for therapies aimed at eliminating cancer stem cells.

What approaches can be used to study the functional role of TEX10 in cancer progression using TEX10 antibodies?

Several sophisticated approaches can be employed to study the functional role of TEX10 in cancer using TEX10 antibodies:

Expression correlation studies in clinical samples:

• Perform IHC with TEX10 antibody on tissue microarrays containing normal tissues and cancer tissues at different stages

• Score TEX10 expression using standardized methods (H-score or Allred score)

• Correlate expression with clinicopathological parameters and patient outcomes

• Analyze public databases (e.g., GEPIA) to validate findings across larger cohorts

Genetic manipulation validation and phenotypic analysis:

• Use TEX10 antibodies to confirm efficiency of genetic manipulation (siRNA, shRNA, CRISPR-Cas9)

• Quantify expression by Western blot before proceeding with functional assays

• Perform proliferation, migration, invasion, and colony formation assays following manipulation

• Analyze effects on cancer-related signaling pathways using phospho-specific antibodies

Subcellular localization and dynamic regulation:

• Conduct fractionation studies and confirm TEX10 distribution using Western blot

• Perform high-resolution immunofluorescence to precisely localize TEX10 within cellular compartments

• Analyze changes in localization under different conditions (stress, treatment, differentiation)

• Co-stain with organelle markers to define exact localization patterns

In vivo tumor models with TEX10 manipulation:

• Establish xenograft models with TEX10-manipulated cells

• Harvest tumors and perform IHC with TEX10 antibody to confirm maintained expression changes

• Analyze tumor growth kinetics, histopathology, and metastatic potential

• Correlate TEX10 expression with tumor aggressiveness parameters

Research has demonstrated that TEX10 promotes proliferation, migration, and invasion of cancer cells in vitro. For instance, in urinary bladder carcinoma, knockdown of TEX10 remarkably suppressed cell proliferation, while overexpression enhanced growth . Migration and invasion assays revealed that TEX10-overexpressing cells showed almost twofold increases in migratory capacity and notable increases in invasion compared to controls . These findings establish TEX10 as a potential therapeutic target in cancer therapy.

How can researchers investigate TEX10's role in radiotherapy resistance using TEX10 antibodies?

Studying TEX10 in radiotherapy resistance models requires careful experimental design and consideration of various methodological aspects:

Model system development and characterization:

• Establish radioresistant cell lines through fractionated radiation exposure

• Characterize TEX10 expression in parent vs. radioresistant derivatives using Western blot

• Perform IHC or IF to analyze TEX10 expression in patient samples from radiotherapy responders vs. non-responders

• Develop xenograft models with varied TEX10 expression for in vivo radiation response studies

Expression dynamics following radiation:

• Measure TEX10 expression at different time points post-radiation using Western blot and IF

• Analyze subcellular localization changes in response to radiation

• Perform pulse-chase experiments to determine if radiation affects TEX10 protein stability

• Correlate TEX10 expression changes with radiation response markers

Functional modulation studies:

• Manipulate TEX10 expression using genetic approaches (overexpression, shRNA, CRISPR)

• Confirm alteration of TEX10 levels using antibody-based detection methods

• Assess radiation sensitivity through clonogenic survival assays, apoptosis measurements, and DNA damage repair kinetics

• Analyze cell cycle progression following radiation in TEX10-manipulated cells

Mechanistic investigations:

• Use TEX10 antibodies for co-immunoprecipitation to identify radiation-induced changes in protein interactions

• Perform chromatin immunoprecipitation to assess TEX10 binding to radiation response genes

• Analyze post-translational modifications of TEX10 following radiation

• Investigate involvement in DNA damage response pathways

Research has demonstrated that TEX10 promotes radiotherapy resistance in urinary bladder carcinoma . This relationship between TEX10 expression and radiotherapy response suggests that targeting TEX10 might enhance the efficacy of radiotherapy in cancer treatment. The development of combination approaches that modulate TEX10 expression or function could potentially overcome radioresistance and improve patient outcomes.

What methods can be used to study TEX10's role in epithelial-mesenchymal transition (EMT) using TEX10 antibodies?

TEX10 has been implicated in promoting epithelial-mesenchymal transition (EMT), a critical process in cancer progression and metastasis. The following methods can be used to investigate this relationship:

Expression correlation analysis:

• Perform dual immunofluorescence with TEX10 antibody and EMT markers (E-cadherin, N-cadherin, vimentin, Snail, Slug)

• Quantify co-expression patterns at single-cell level using confocal microscopy

• Analyze correlation between TEX10 expression and EMT marker profiles in tissue sections

• Compare EMT marker expression in TEX10-high versus TEX10-low regions within heterogeneous tumors

Functional relationship studies:

• Manipulate TEX10 expression using genetic approaches (siRNA, overexpression)

• Validate expression changes using Western blot with TEX10 antibody

• Analyze EMT marker expression following TEX10 manipulation

• Assess phenotypic changes associated with EMT (morphology, migration, invasion)

Regulatory mechanism investigation:

• Perform chromatin immunoprecipitation using TEX10 antibody to identify potential binding to EMT gene promoters

• Use co-immunoprecipitation to identify interactions between TEX10 and known EMT regulators

• Analyze changes in EMT-related signaling pathways (TGF-β, Wnt, Notch) following TEX10 manipulation

• Investigate post-translational modifications of EMT-related transcription factors in relation to TEX10 expression

In vivo metastasis model analysis:

• Establish metastatic models using TEX10-manipulated cells

• Analyze primary tumors and metastatic sites using IHC with TEX10 antibody

• Compare EMT marker expression between primary and metastatic lesions

• Correlate TEX10 expression with metastatic potential and EMT phenotype

Research has demonstrated that TEX10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma, suggesting its importance in cancer progression and metastasis . Understanding the molecular mechanisms by which TEX10 regulates EMT could provide insights into metastasis prevention strategies and identify new therapeutic targets for advanced cancers.

What are the common challenges when working with TEX10 antibodies and how can they be addressed?

Researchers working with TEX10 antibodies may encounter several technical challenges that can be addressed through appropriate troubleshooting strategies:

Western blot signal optimization:

• Challenge: Weak or inconsistent signal

• Solutions:

  • Increase antibody concentration (try 1:500 if 1:2000 yields weak signal)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading amount (40-60 μg total protein)

  • Use enhanced chemiluminescence detection systems

  • Ensure complete transfer by extending transfer time for this large protein

  • Include positive controls (HeLa cells recommended)

Immunostaining background reduction:

• Challenge: High background in IHC/IF applications

• Solutions:

  • Optimize blocking conditions (extend blocking time to 1-2 hours)

  • Dilute primary antibody further (starting at 1:100 and titrating as needed)

  • Increase washing steps duration and frequency

  • Use more specific secondary antibodies with minimal cross-reactivity

  • For tissues, test different antigen retrieval methods (compare pH 6.0 vs. pH 9.0)

  • Include absorption controls with immunizing peptide when available

Specificity verification:

• Challenge: Ensuring signal represents true TEX10 detection

• Solutions:

  • Validate with genetic controls (siRNA knockdown, CRISPR knockout)

  • Test multiple antibodies targeting different epitopes

  • Perform peptide competition assays when immunizing peptide is available

  • Compare with mRNA expression data

  • Include positive and negative control tissues/cells

Immunoprecipitation optimization:

• Challenge: Poor IP efficiency

• Solutions:

  • Pre-clear lysates thoroughly to reduce non-specific binding

  • Optimize antibody amount (typically 2-5 μg per IP reaction)

  • Use protein A/G beads with high binding capacity

  • Increase incubation time for antibody-antigen binding (overnight at 4°C)

  • Modify lysis and wash buffer compositions to preserve interactions

  • Consider crosslinking antibody to beads for cleaner results

Research experience suggests that TEX10 antibodies generally perform well in standard applications when used at recommended dilutions, but optimization for specific experimental conditions is often necessary . The observed molecular weight of TEX10 in Western blot applications is typically 95-100 kDa, which should be used as a reference point for validating antibody specificity .

How should researchers interpret and troubleshoot discrepancies in TEX10 expression data across different techniques?

When faced with discrepancies in TEX10 expression data across different techniques, researchers should consider several factors and follow a systematic troubleshooting approach:

Common sources of discrepancy:

• Methodological differences:

  • Different sensitivity thresholds between techniques (WB vs. IHC vs. qPCR)

  • Post-translational modifications detected by protein-based but not RNA-based methods

  • Epitope accessibility varying between applications (certain fixation methods may mask epitopes)

  • Different antibody clones targeting different TEX10 domains may give varying results

• Sample-related variables:

  • Heterogeneity within tissue samples leading to sampling bias

  • Fixation artifacts affecting protein detection in IHC

  • RNA quality issues affecting qPCR results

  • Protein extraction efficiency differences between samples

Systematic resolution approach:

• Comprehensive validation:

  • Perform parallel analysis with multiple techniques on the same samples

  • Use multiple antibodies targeting different TEX10 epitopes

  • Include appropriate positive and negative controls in each experiment

  • Validate with genetic approaches (siRNA/CRISPR)

• Technical standardization:

  • Standardize sample preparation methods across experiments

  • Use consistent antibody lots and dilutions

  • Implement rigorous normalization procedures

  • Document all experimental conditions meticulously

• Data integration strategies:

  • Analyze correlations between techniques across multiple samples

  • Consider biological context when interpreting discrepancies

  • Weight evidence based on technical rigor of each method

  • Apply appropriate statistical analysis to determine significance of differences

What are the considerations for multiplex immunofluorescence applications with TEX10 antibodies?

Optimizing TEX10 antibodies for multiplex immunofluorescence applications requires careful consideration of several technical factors:

Antibody selection and validation:

• Choose TEX10 antibody with demonstrated specificity and minimal background

• Validate performance in single-color IF before attempting multiplexing

• Test for cross-reactivity with other primary antibodies in the multiplexing panel

• Consider using monoclonal antibodies when available for higher specificity

Panel design considerations:

• Select antibodies raised in different host species to avoid cross-reactivity

• Choose fluorophores with minimal spectral overlap

• Consider signal intensity balancing (TEX10 may require amplification if expression is low)

• Include appropriate controls for each antibody in the panel

• Design panel to answer specific biological questions about TEX10's relationship with other markers

Sequential staining optimization:

• For highly complex panels, consider sequential staining with stripping or quenching

• Validate complete removal/inactivation of TEX10 antibody before subsequent rounds

• Determine optimal antibody order (typically start with lower abundance targets)

• Compare results from sequential versus simultaneous staining approaches

Signal amplification strategies:

• For low-abundance TEX10 expression, consider tyramide signal amplification (TSA)

• Optimize amplification conditions to prevent oversaturation

• Balance amplification across all markers in the panel

• Validate that amplification doesn't increase background or non-specific binding

Image acquisition and analysis:

• Use appropriate exposure settings to prevent bleed-through between channels

• Perform spectral unmixing if necessary to resolve overlapping signals

• Implement automated analysis algorithms for unbiased quantification

• Consider machine learning approaches for complex pattern recognition

Multiplex immunofluorescence with TEX10 antibodies could be particularly valuable for studying TEX10's relationship with stemness markers (Sox2, Nanog, Oct4), proliferation markers (Ki-67, PCNA), and other cancer-related proteins in the spatial context of heterogeneous tumors . This approach could provide insights into the molecular networks involving TEX10 and their roles in cancer progression.

How might TEX10 antibodies be used in developing potential cancer biomarkers?

TEX10's differential expression in cancer tissues and association with patient outcomes suggest potential applications in biomarker development:

Prognostic biomarker development:

Predictive biomarker exploration:

• Analyze TEX10 expression in pre-treatment biopsies and correlate with therapy response

• Compare TEX10 levels in responders versus non-responders to specific therapies

• Investigate TEX10 as a biomarker for radiotherapy response, given its role in radioresistance

• Evaluate TEX10 in combination with other markers to create predictive signatures

Liquid biopsy applications:

• Develop protocols for TEX10 detection in circulating tumor cells using immunofluorescence

• Investigate TEX10 protein or autoantibodies in patient serum

• Explore TEX10 detection in extracellular vesicles from patient blood or urine

• Correlate with tissue expression and clinical outcomes

Companion diagnostic potential:

• If TEX10-targeted therapies are developed, establish antibody-based assays to identify suitable patients

• Determine threshold expression levels for therapeutic response

• Develop standardized diagnostic kits with appropriate controls

• Validate analytical performance across different laboratories

The role of TEX10 in disease-free survival has been demonstrated in urinary bladder carcinoma patients, where patients with low TEX10 levels showed improved survival outcomes . This relationship suggests that TEX10 quantification using antibody-based methods could provide valuable prognostic information. The GEPIA online database analysis confirmed that patients with low-level TEX10 showed improved disease-free survival, further supporting its potential as a biomarker .

How can researchers investigate post-translational modifications of TEX10 using TEX10 antibodies?

Investigating post-translational modifications (PTMs) of TEX10 requires specialized approaches leveraging TEX10 antibodies:

Phosphorylation analysis:

• Immunoprecipitate TEX10 using specific antibodies followed by phospho-specific Western blotting

• Perform reverse approach: immunoprecipitate with phospho-specific antibodies and detect TEX10

• Use phosphatase inhibitors during sample preparation to preserve phosphorylation state

• Compare phosphorylation status under different cellular conditions (stress, treatment, cell cycle)

SUMOylation investigation:

• Given TEX10's known SUMO-controlled distribution, analyze SUMOylation through:

  • Immunoprecipitation with TEX10 antibody followed by SUMO detection

  • Expression of tagged SUMO constructs and analysis of TEX10 modification

  • Compare nuclear/nucleolar localization with SUMOylation status

  • Investigate effects of SUMOylation inhibitors on TEX10 function

Mass spectrometry-based PTM mapping:

• Immunoprecipitate TEX10 using specific antibodies

• Perform mass spectrometry analysis to identify all PTMs

• Develop PTM-specific antibodies when key modifications are identified

• Validate functional significance through mutagenesis of modified residues

PTM dynamics in cancer progression:

• Compare TEX10 PTM patterns between normal and cancer tissues

• Analyze changes in modification status during therapy resistance development

• Correlate specific modifications with TEX10 functional activities

• Investigate enzymes responsible for TEX10 modifications as potential therapeutic targets

Research has indicated that TEX10's distribution is controlled by SUMOylation, which coordinates the rate of ribosome formation . This regulatory mechanism may be particularly relevant in cancer biology, where altered ribosome biogenesis can contribute to uncontrolled proliferation. Furthermore, understanding how PTMs affect TEX10's interactions with the MLL1/MLL complex could provide insights into its role in epigenetic regulation and identify new therapeutic opportunities.

What potential therapeutic applications might emerge from TEX10 research using antibody-based approaches?

Research on TEX10 using antibody-based approaches could lead to several potential therapeutic applications:

Target validation for drug development:

• Use TEX10 antibodies to confirm target engagement in drug screening assays

• Validate on-target effects of TEX10-directed therapies

• Analyze changes in TEX10 protein levels, localization, or interactions following treatment

• Develop cellular assays for high-throughput screening of TEX10 inhibitors

Antibody-drug conjugates (ADCs):

• If TEX10 shows cell-surface expression in certain contexts, develop ADCs targeting TEX10

• Evaluate internalization dynamics of TEX10 antibodies

• Optimize linker chemistry and payload selection

• Test efficacy and specificity in preclinical models

Combination therapy rational design:

• Identify synthetic lethal interactions with TEX10 inhibition

• Use TEX10 antibodies to monitor expression in response to various therapies

• Develop rational combinations targeting TEX10 and interacting pathways

• Design sequential therapy approaches based on TEX10 expression dynamics

Radiotherapy sensitization strategies:

• Given TEX10's role in radioresistance , develop approaches to target TEX10 before radiotherapy

• Monitor TEX10 expression during fractionated radiotherapy using antibody-based methods

• Identify optimal timing for combined TEX10 inhibition and radiation

• Develop biomarker strategies to select patients who would benefit from TEX10 targeting

Cancer stem cell targeting:

• Leverage TEX10's role in cancer stemness to develop anti-CSC therapeutics

• Use TEX10 antibodies to identify and isolate CSC populations

• Monitor changes in CSC populations following TEX10-targeted therapy

• Develop combination approaches targeting both TEX10 and other CSC-related pathways

The demonstrated roles of TEX10 in cancer cell proliferation, migration, invasion, stemness, and radiotherapy resistance make it a promising target for therapeutic intervention . Its involvement in multiple cancer types suggests broad potential applications. The clear correlation between TEX10 expression and disease progression provides a strong rationale for developing therapeutic strategies targeting this protein, with antibody-based approaches serving as critical tools for development and validation.